Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiasthma Drugs: β2-Adrenoceptor Agonists

Antiasthma Drugs: β₂-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

Inhaled Medications

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...

Drugs Used in Lower Respiratory Disorders: Overview

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...

Asthma-IV: Diagnostic and Management

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prolonged-release pirfenidone in patients with pulmonary fibrosis as a phenotype of post-acute sequelae of COVID-19 pneumonia. Safety and efficacy.

Respiratory medicine·2023

Same author

The mechanical and chemical stability of the interfaces in bioactive materials: The substrate-bioactive surface layer and hydroxyapatite-bioactive surface layer interfaces.

Materials science & engineering. C, Materials for biological applications·2020

Same author

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.

Leukemia·2020

Same author

A continuous-time Markov model approach for modeling myelodysplastic syndromes progression from cross-sectional data.

Journal of biomedical informatics·2020

Same author

Pharmacology and Therapeutics of Bronchodilators Revisited.

Pharmacological reviews·2019

Same author

Bioactive materials: In vitro investigation of different mechanisms of hydroxyapatite precipitation.

Acta biomaterialia·2019

Search research articles

Related Experiment Video

Updated: Jul 3, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Novel long-acting bronchodilators for COPD and asthma.

M Cazzola¹, M G Matera

¹Unit of Respiratory Diseases, Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy. mario.cazzola@uniroma2.it

British Journal of Pharmacology

|July 8, 2008

Summary

Simplifying asthma and COPD treatment with once-daily medications improves patient adherence and outcomes. New ultra long-acting bronchodilators and combination inhalers are under development for better disease management.

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Related Experiment Videos

Last Updated: Jul 3, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Area of Science:

Respiratory Medicine
Pharmacology
Drug Development

Background:

Asthma and COPD management requires improved patient adherence to therapy.
Reducing medication frequency to once-daily administration is a key strategy for enhancing adherence and clinical outcomes.
Current treatments often involve multiple daily doses, posing challenges for patient compliance.

Purpose of the Study:

To review the development of once-daily bronchodilator therapies for asthma and COPD.
To explore novel combination products and dual-acting molecules for simplified treatment regimens.
To highlight the potential impact of these advancements on patient care and disease management.

Main Methods:

Review of ongoing research and development of new long-acting bronchodilators.
Analysis of emerging combination therapies, including ultra long-acting beta2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs).
Investigation into novel dual-pharmacology molecules, such as M3 antagonist-beta2 agonist (MABA) bronchodilators.

Main Results:

Several once-daily ultra long-acting beta2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) are in development for asthma and COPD.
Combination inhalers featuring LABA+LAMA are being evaluated to further simplify treatment.
Development of MABA bronchodilators represents a novel approach with potential to revolutionize treatment.

Conclusions:

Once-daily dosing strategies, including novel bronchodilators and combination products, are crucial for improving asthma and COPD management.
The development of dual-acting MABA bronchodilators offers a promising new avenue for simplified and effective treatment.
Advancements in inhaled therapies aim to enhance patient adherence, compliance, and overall clinical outcomes.